1. A Measure of Illness Awareness in Individuals With Nicotine Dependence—Nicotine Use Awareness and Insight Scale
- Author
-
Ariel Graff-Guerrero, Yasaman Kambari, Lena C. Quilty, Julia Kim, Jianmeng Song, Peter Selby, Philip Gerretsen, Fumihiko Ueno, Bruce G. Pollock, Anmol Taggar, and Fernando Caravaggio
- Subjects
Adult ,Male ,Nicotine ,Adolescent ,Psychometrics ,Original Investigations ,Validity ,Electronic Nicotine Delivery Systems ,Affect (psychology) ,Cronbach's alpha ,Surveys and Questionnaires ,Humans ,Medicine ,Reliability (statistics) ,business.industry ,Public Health, Environmental and Occupational Health ,Discriminant validity ,Reproducibility of Results ,Tobacco Use Disorder ,Middle Aged ,Exploratory factor analysis ,Scale (social sciences) ,Female ,business ,Clinical psychology ,medicine.drug - Abstract
Introduction Impaired illness awareness or the inability to recognize that one has a dependence on nicotine may be a major barrier to seeking cessation treatment. To better understand the role of impaired illness awareness on treatment-seeking behavior and clinical outcomes, we developed and examined the psychometric properties of a novel scale measuring illness awareness in individuals with dependence on nicotine. Aims and Methods We developed the Nicotine Use Awareness and Insight Scale (NAS), a 7-item self-report measure to assess the theoretical construct of illness awareness in individuals with dependence on nicotine (www.illnessawarenessscales.com). Data from participants 18 years of age or older were collected via a web-based survey company, Dynata. Participants with moderate dependence on nicotine were included, defined by a score of four or more on the Fagerström Test for Cigarette Dependence (FTCD) or the FTCD adapted for electronic cigarettes (eFTCD). Results A total of 100 participants (mean [SD] age = 49.1 [16.1] years, 52% women) that met the inclusion criteria for either FTCD (n = 50) or eFTCD (n = 50) were included. The NAS demonstrated good convergent (r = .74, p < .001) and discriminant validity (r = .03, p = .786). It also demonstrated good internal consistency (Cronbach’s alpha = 0.78) and one-month test-retest reliability (intra-class correlation = 0.86). An exploratory factor analysis yielded the retention of two components. Conclusions The NAS is a novel scale to asses illness awareness in individuals with dependence on nicotine. This study provides initial support for the psychometric validity and reliability of NAS. Implications The NAS may be used in research and clinical practice to evaluate the impact of impaired illness awareness on treatment-seeking behavior and clinical outcomes.
- Published
- 2021